The Iowa-Mayo SPORE Biospecimens Shared Resource provides a coordinated, centralized, and dedicated core for the procurement, processing and annotafion of biospecimens from lymphoma patients and pafients with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL). The goal of the Biospecimens Core is to procure a variety of biologic specimens on all patients involved in UI/MC SPORE protocols and all newly diagnosed lymphoma pafients seen at the University of lowa and the Mayo Clinic Rochester, who are enrolled into the Molecular Epidemiology Resource (MER).
The specific aims ef the Biospecimens Core are: 1) To provide accurate classification of all lymphomas from patients enrolled onto SPORE protocols and the MER;2) To collect, process, bank and distribute biologic specimens from lowa and Mayo lymphoma patients for translafional research;3) To track all biospecimens and ensure linkage to clinical, outcome and related data;and 4) Te serve as a resource of expertise, collaborative support and service for projects. All specimens are collected and processed under tight quality control, and distributed to SPORE researchers or banked for future SPORE research projects. These activities are tracked using a sophisticated database that merges the activities at lowa and Mayo, and allows integration with clinical and other data collected in research projects. The Core provides specialized expertise in working with lymphoma biospecimens and is closely aligned with institutional research cores and shared resources, but does not duplicate them. During the last funding period, the Core collected biospecimens from 7 SPORE clinical trials (>1000 samples from 193 pafients). The Core also reviewed and classified 2,461 pafients for enrollment into the MER, and collected germline DNA on >2S00 and serum on >2100 ofthe MER patients. The Core additionally banked frozen cells on -400 patients. The Cere has supported all of the full projects and multiple Developmental and Career Development projects. There has been extensive utilization of biospecimens, including use of paraffin and frozen tissue;frozen cells;germline DNA;and serum and plasma, all leading to extensive publications involving the Core. The Biospecimens Core has also partnered on other projects that have obtained extramural funding to support epidemiologic studies, family studies, genome-wide association studies, inter-SPORE studies, and other ROI and POl projects. In the next grant cycle, we will continue to accrue new patient samples to the bank and work with investigators to utilize this increasingly valuable resource to support translational research projects in lymphoma.

Public Health Relevance

Well-characterized, pathologically and clinically annotated tumor tissues from patients with malignant lymphoma are a critical and valuable resource for translating the basic molecular and biological understanding of lymphomas into improved treatments for patients. The UI/MC Lymphoma SPORE meets these needs by linking the biospecimens resource with ether ceres and the MER.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Iowa
Iowa City
United States
Zip Code
Link, Brian K (2017) Early Relapse in Follicular Lymphoma: High Risks and High Stakes. J Oncol Pract 13:810-811
Ding, Wei; LaPlant, Betsy R; Call, Timothy G et al. (2017) Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 129:3419-3427
Ammann, Eric M; Shanafelt, Tait D; Larson, Melissa C et al. (2017) Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clin Lymphoma Myeloma Leuk 17:e11-e25
Wafa, Emad I; Geary, Sean M; Goodman, Jonathan T et al. (2017) The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response. Acta Biomater 50:417-427
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Tanaka, Yoshimasa; Iwasaki, Masashi; Murata-Hirai, Kaoru et al. (2017) Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug. Sci Rep 7:5987
Wang, Xueju; Dasari, Surendra; Nowakowski, Grzegorz S et al. (2017) Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. Oncotarget 8:26245-26255
Scott, David W; Abrisqueta, Pau; Wright, George W et al. (2017) New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. J Clin Oncol 35:1668-1677
Tracy, S I; Maurer, M J; Witzig, T E et al. (2017) Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. Blood Cancer J 7:e595
Law, Philip J; Berndt, Sonja I; Speedy, Helen E et al. (2017) Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nat Commun 8:14175

Showing the most recent 10 out of 337 publications